Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

NCT05474885 is registered in ClinicalTrials.gov with iCell Gene Therapeutics as lead sponsor.

NCT NCT05474885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05474885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
Lead sponsor
iCell Gene Therapeutics
Phase
Phase 1
Overall status
Unknown status
Start date
April 1, 2022
Completion date
April 30, 2025
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory, systemic lupus erythematosus (sle)